Download Files:
PA-9
$200 – $4,800
Products Details
Product Description
– PA-9 is a pituitary adenylate cyclase-activating polypeptide (PACAP) type I (PAC1) receptor antagonist. PA-9 dose dependently inhibits PACAP-induced cAMP elevation with an IC50 of 5.6 nM. PA-9 can be used for the research of neuropathic and/or inflammatory pain[1].
Web ID
– HY-129421
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C17H18N6O2
References
– [1]Takasaki I, et al. In Silico Screening Identified Novel Small-molecule Antagonists of PAC1 Receptor. J Pharmacol Exp Ther. 2018 Apr;365(1):1-8.
CAS Number
– 1436004-46-4
Molecular Weight
– 338.36
Compound Purity
– 99.60
SMILES
– O=C(C(C1)CN(C2=NNC3=C2C=CC=C3)C1=O)NCCC4=CN=CN4
Clinical Information
– No Development Reported
Research Area
– Inflammation/Immunology; Neurological Disease
Solubility
– DMSO : 250 mg/mL (ultrasonic)
Target
– Others
Pathway
– Others
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
